keyword
MENU ▼
Read by QxMD icon Read
search

rchop

keyword
https://www.readbyqxmd.com/read/30496802/p53-expression-in-large-b-cell-lymphomas-with-myc-extra-copies-and-cd99-expression-in-large-b-cell-lymphomas-in-relation-to-myc-status
#1
Aida Richardson, Da Zhang, Janet Woodroof, Wei Cui
p53 expression and MYC-extra copies (MYC-EC) have been reported to serve as independent adverse prognostic markers in patients with diffuse large B-cell lymphoma (DLBCL). However, the impact of p53 expression in MYC-EC lymphomas has not been delineated. Conversely, CD99 expression has been shown to have a positive impact on survival in patients with germinal center-type DLBCL, yet nothing is reported about the impact of CD99 expression and MYC status. This is the first study to evaluate p53 expression in MYC-EC lymphomas and CD99 expression in relation to MYC status...
November 26, 2018: Human Pathology
https://www.readbyqxmd.com/read/30410035/lenalidomide-plus-r-chop21-in-newly-diagnosed-diffuse-large-b-cell-lymphoma-dlbcl-long-term-follow-up-results-from-a-combined-analysis-from-two-phase-2-trials
#2
A Castellino, A Chiappella, B R LaPlant, L D Pederson, G Gaidano, W R Macon, G Inghirami, C B Reeder, A Tucci, R L King, A Congiu, J M Foran, V Pavone, C E Rivera, M Spina, S M Ansell, F Cavallo, A L Molinari, Giovannino Ciccone, T M Habermann, T E Witzig, U Vitolo, G S Nowakowski
Lenalidomide-RCHOP (R2-CHOP21) has been shown to be safe and effective in patients with untreated diffuse large B-cell lymphoma (DLBCL). The aim of this analysis is to report long-term outcome and toxicities in newly diagnosed DLBCL patients who received R2-CHOP21 in two independent phase 2 trials, conducted by Mayo Clinic (MC) and Fondazione Italiana Linfomi (FIL). All patients received R-CHOP21 plus lenalidomide. Long-term progression-free survival (PFS), time to progression (TTP), overall survival (OS) and late toxicities and second tumors were analyzed...
November 8, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/30277099/adverse-events-resource-use-and-economic-burden-associated-with-mantle-cell-lymphoma-a-real-world-assessment-of-privately-insured-patients-in-the-united-states
#3
Ravi K Goyal, Saurabh P Nagar, Shaum M Kabadi, James A Kaye, Brian Seal, Anthony R Mato
In view of recent therapeutic advances in mantle cell lymphoma (MCL), the aim of this retrospective cohort analysis was to assess treatment patterns, adverse events (AEs), resource utilization, and health care costs in patients with MCL in a US-based commercial claims database. A total of 783 patients with MCL (median age = 65 years) were selected. Among patients receiving systemic therapy (n = 457), the most common treatment regimens were bendamustine/rituximab (BR) (41.1%), rituximab/cyclophosphamide/doxorubicin/vincristine (RCHOP) (26...
October 2, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/30113708/population-based-outcome-analysis-of-diffuse-large-b-cell-lymphoma-in-people-living-with-hiv-infection-and-competent-individuals
#4
Annarita Conconi, Emanuele Zucca, Gloria Margiotta-Casaluci, Katharine Darling, Barbara Hasse, Manuel Battegay, Cornelia Staehelin, Urban Novak, Patrick Schmid, Alexandra Scherrer, Stephan Dirnhofer, Ivo Kwee, Luca Nassi, Franco Cavalli, Gianluca Gaidano, Francesco Bertoni, Enos Bernasconi
The prognostic factors and outcome of 58 acquired immunodeficiency syndrome-related diffuse large B-cell lymphoma (AR-DLBCL) patients from the Swiss HIV Cohort Study, diagnosed from 2004 to 2011, were compared with those of 326 immunocompetent (IC)-DLBCL from the Hematology Division of the Amedeo Avogadro University (Italy) and the Oncology Institute of Southern Switzerland. Median follow-up was 6 years; 5-year overall survival (OS) was 68% (95% CI: 63%-73%) in IC-DLBCL and 63% (95% CI: 49%-75%) in AR-DLBCL (P = ...
August 16, 2018: Hematological Oncology
https://www.readbyqxmd.com/read/30112341/diffuse-large-b-cell-lymphoma-an-institutional-analysis
#5
Ajay Gogia, Chandan K Das, Lalit Kumar, Atul Sharma, Akash Tiwari, M C Sharma, Soumya Mallick
Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma. We conducted a retrospective study to analyze the clinicopathological characteristics, cell of origin, response to therapy, and the outcome of patients with DLBCL. Materials and Methods: This was a retrospective study which included all patients with DLBCL registered at our center, between May 1, 2013, and July 31, 2015. The data regarding demography, clinical presentation, histopathology, stage, prognostic index, treatment, and treatment-related outcome were collected from prospectively maintained clinical case records of the patients...
July 2018: South Asian Journal of Cancer
https://www.readbyqxmd.com/read/29983626/primary-bone-lymphomas-retrospective-analysis-of-42-consecutive-cases
#6
Telma Murias Dos Santos, Juan Pablo Zumárraga, Fábio Mazetti Reaes, Carlos Henrique Maçaneiro, André Mathias Baptista, Olavo Pires DE Camargo
Objective: It is difficult to define parameters for management and factors associated with primary bone lymphoma (PBL). This article presents the experience in a single institution with 42 patients with PBL over a 16-year period (2000-2016). Methods: Fifty-five patients were retrospectively evaluated, and forty-two were included (76.3%). Results: Median age at diagnosis was 51.5 years, and median follow-up was 102.7 months. One patient had HIV...
March 2018: Acta Ortopedica Brasileira
https://www.readbyqxmd.com/read/29603428/retrospective-analysis-of-frontline-treatment-efficacy-in-elderly-patients-with-diffuse-large-b-cell-lymphoma
#7
Chieh-Lung Cheng, Jia-Hau Liu, Sheng-Chieh Chou, Ming Yao, Jih-Luh Tang, Hwei-Fang Tien
OBJECTIVES: To investigate the effectiveness of 2 chemotherapeutic regimens, bendamustine plus rituximab (BR) or reduced-dose cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab (RD-R-CHOP), in elderly patients with treatment-naïve diffuse large B-cell lymphoma. METHODS: A retrospective study was conducted to investigate the efficacy and safety of 2 frontline regimens, BR and RD-R-CHOP, in patients aged ≥75 years unfit for R-CHOP. RESULTS: From January 2011 to December 2015, 26 patients received BR and 34 RD-R-CHOP...
July 2018: European Journal of Haematology
https://www.readbyqxmd.com/read/29531316/rapid-real-time-pathology-review-for-ecog-acrin-1412-a-novel-and-successful-paradigm-for-future-lymphoma-clinical-trials-in-the-precision-medicine-era
#8
RANDOMIZED CONTROLLED TRIAL
Rebecca L King, Grzegorz S Nowakowski, Thomas E Witzig, David W Scott, Richard F Little, Fangxin Hong, Randy D Gascoyne, Brad S Kahl, William R Macon
ECOG/ACRIN 1412 (E1412) is a randomized, phase II open-label study of lenalidomide/RCHOP vs. RCHOP alone in adults with newly diagnosed de novo diffuse large B-cell lymphoma (DLBCL) and requires NanoString gene expression profiling (GEP) for cell-of-origin testing. Because of high ineligibility rate on retrospective expert central pathology review (ECPR), real-time (RT) ECPR was instituted to confirm diagnosis and ensure adequate tissue for GEP prior to study enrollment. Goal was notification of eligibility within 2 working days (WD)...
February 28, 2018: Blood Cancer Journal
https://www.readbyqxmd.com/read/29492077/cns-relapse-of-diffuse-large-b-cell-lymphoma-a-single-centre-experience
#9
Adil Nazir, Fawad, Neelam Siddique, Abdul Hameed
Background and Objective: Central nervous system (CNS) relapse of diffuse large B cell lymphoma (DLBCL) is relatively uncommon and nearly fatal. Two years CNS relapse risk is 0.8% in low, 3.9% in intermediate and 12% in high risk patients. Our aim was to study, the baseline characteristics and outcome in term of median survival of DLBCL patients with CNS relapse. Methods: This is a retrospective analysis. All patients of DLBCL with CNS relapse from 2006 to 2014 were included...
November 2017: Pakistan Journal of Medical Sciences Quarterly
https://www.readbyqxmd.com/read/29488576/-rectal-diffuse-large-b-cell-lymphoma-appearing-after-immunosuppression-for-ulcerative-colitis-report-of-one-case
#10
Rodrigo Quera, Lilian Flores, Daniela Simian, Udo Kronberg, María Teresa Vial, David Ladrón de Guevara, María José García-Rodríguez
Primary colorectal lymphoma is a rare form of presentation of gastrointestinal tract lymphomas. Inflammatory bowel disease and its treatment are risk factors for its development. We report a 47-year-old male patient with Ulcerative Colitis of two years of evolution, treated initially with azathioprine and later on with infliximab. Due to a relapse in symptoms after the second dose of infliximab, a new coloncoscopy was performed showing a rectal ulcerative lesion, corresponding to a large cell Non-Hodgkin's Lymphoma...
October 2017: Revista Médica de Chile
https://www.readbyqxmd.com/read/29469072/long-term-outcome-of-diffuse-large-b-cell-lymphoma-impact-of-biosimilar-rituximab-and-radiation
#11
P Ganesan, T G Sagar, K Kannan, V Radhakrishnan, S Rajaraman, A John, S Sundersingh, V Mahajan, T S Ganesan
INTRODUCTION: Rituximab (R)-CHOP improves survival over CHOP in diffuse large B-cell lymphoma (DLBCL). The availability of biosimilar rituximab in India has increased access of this drug. We report on the impact of treatment on outcomes with special emphasis on the impact of biosimilar rituximab and radiation. METHODS: Outcomes of adults (age 15-60 years) treated with CHOP+/- Rituximab radiation were analyzed retrospectively to look at baseline features, treatment, and event-free and overall survival (EFS and OS)...
April 2017: Indian Journal of Cancer
https://www.readbyqxmd.com/read/29397836/-significance-of-h3k27me3-and-ezh2-in-predicting-the-therapeutic-efficacy-of-diffuse-large-b-cell-lymphoma
#12
Yu-Jie Deng, Gang Chen, Wei-Feng Zhu, Xiao-Hui Chen, Hua-Lan Hong, Li-Ming Huang, Xi Shi, Jun-Min Chen
OBJECTIVE: To investigate the significance of H3K27me3 and its methyltransferase EZH2 in predicting the short-term and long-term outcome of newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL). METHODS: The paraffin wax speciments of 102 DLBCL patients in Fujian Medical University Cancer Hospital were collected. The expression of H3K27me3, EZH2 and BCL-2 protein were detected using tissue array made by tissue microarray(TMA) technique and immunohistochemistry method...
February 2018: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://www.readbyqxmd.com/read/29338665/adjuvant-radiotherapy-in-patients-with-diffuse-large-b-cell-lymphoma-in-advanced-stage-iii-iv-improves-the-outcome-in-the-rituximab-era
#13
Agustin Avilès, Maria-Jesus Nambo, Angel Calva, Natividad Neri, Sergio Cleto, Luis Silva
OBJECTIVES: To assess the efficacy and toxicity of adjuvant radiotherapy (RT) in patients with diffuse large B-cell lymphoma (DLBCL) and nodal bulky disease, on complete response, after six cycles of RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone), we began an open-label clinical trial in a large cohort with longer follow-up to evaluate the outcome measured from progression-free survival (PFS) and overall survival (OS). PATIENTS AND METHODS: Between 2006 and 2010, 258 consecutive patients with DLBCL and nodal bulky disease (tumor mass >10 cm) were randomly assigned to receive either RT (involved field, 30 Gy) (127 patients) or no (control group) (131 patients)...
January 17, 2018: Hematology (Amsterdam, Netherlands)
https://www.readbyqxmd.com/read/29202805/clinical-significance-of-pcdh10-promoter-methylation-in-diffuse-large-b-cell-lymphoma
#14
Wenting Huang, Xuemin Xue, Ling Shan, Tian Qiu, Lei Guo, Jianming Ying, Ning Lu
BACKGROUND: PCDH10, one of the non-clustered protocadherins, is identified as a tumor suppressor gene in many tumors. Recently, promoter methylation of PCDH10 was found in diffuse large B-cell lymphoma (DLBCL) but not in normal lymph nodes, suggesting that its epigenetic aberrance is essential to the lymphomagenesis. However, there are few studies on the clinicopathological relevance and prognostic significance of PCDH10 methylation status in DLBCL. METHODS: One hundred-seven cases of DLBCL between Jan 2009 and Jul 2010 were selected to extract genomic DNA and perform bisulfite modification...
December 4, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29102414/are-we-choosing-wisely-in-lymphoma-excessive-use-of-surveillance-ct-imaging-in-patients-with-diffuse-large-b-cell-lymphoma-dlbcl-in-long-term-remission
#15
Matthew C Cheung, Nicole Mittmann, Craig C Earle, Farah Rahman, Ning Liu, Simron Singh
INTRODUCTION: The use of surveillance computed tomography (CT) imaging in patients with diffuse large B-cell lymphoma in remission is neither effective nor cost-effective. The American Society of Hematology Choosing Wisely (CW) campaign, in particular, emphasizes the lack of benefit beyond 2 years of completion of therapy. We sought to describe the real-world practice of surveillance imaging. PATIENTS AND METHODS: We used population-based health system administrative databases from Ontario, Canada...
January 2018: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29086009/incidence-of-interstitial-pneumonitis-in-non-hodgkin-s-lymphoma-patients-receiving-immunochemotherapy-with-pegylated-liposomal-doxorubicin-and-rituximab
#16
Ting Zhou, Qian Shen, Hui Peng, Tengfei Chao, Lihong Zhang, Liu Huang, Kaixiang Yang, Sudip Thapa, Shiying Yu, Yongsheng Jiang
Pneumonitis is a rare but severe and potentially fatal adverse effect in chemotherapy of lymphoma. This study is aimed to investigate the incidence of interstitial pneumonitis in non-Hodgkin's lymphoma (NHL) patients receiving immunochemotherapy with pegylated liposomal doxorubicin and rituximab. Lymphoma patients were retrospectively reviewed, and eligible patients were included in this study. According to the chemotherapy regimens, patients were classified in four groups: combination of vincristine, cyclophosphamide, doxorubicin, and prednisone (CHOP group) with rituximab (RCHOP group) and combination of vincristine, cyclophosphamide, pegylated liposomal doxorubicin and prednisone (CDOP group) with rituximab (RCDOP group)...
January 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29065744/exploring-the-potential-cost-effectiveness-of-precision-medicine-treatment-strategies-for-diffuse-large-b-cell-lymphoma
#17
Qiushi Chen, Ashley D Staton, Turgay Ayer, Daniel A Goldstein, Jean L Koff, Christopher R Flowers
Activated B-cell-like (ABC) diffuse large B-cell lymphoma (DLBCL) is associated with worse survival after standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP) chemoimmunotherapy compared to germinal center B-cell-like (GCB) subtype. Preliminary evidence suggests that benefits from novel agents may vary by subtype. Hypothesizing that treatment stratified by DLBCL subtype could be potentially cost-effective, we developed micro-simulation models to compare three first-line treatment strategies: (1) standard RCHOP for all patients (2) subtype testing followed by RCHOP for GCB and novel treatment for ABC DLBCL, and (3) novel treatment for all patients...
July 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28952038/double-hit-large-b-cell-lymphoma
#18
REVIEW
Yousef Khelfa, Yehuda Lebowicz, Muhammad Omer Jamil
Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL), accounting for approximately 25% of NHL cases. It is a heterogeneous group of diseases. BCL2, BCL6, and MYC are the most frequent mutated genes in DLBCL. Double-hit lymphoma (DHL) is an aggressive form of DLBCL with an unmet treatment need, in which MYC rearrangement is present with either BCL2 or BCL6 rearrangement. Patients typically present with a rapidly growing mass with B symptoms. DHL has been linked to very poor outcomes when treated with RCHOP chemotherapy...
September 26, 2017: Current Oncology Reports
https://www.readbyqxmd.com/read/28884033/high-grade-b-cell-neoplasm-with-surface-light-chain-restriction-and-tdt-coexpression-evolved-in-a-myc-rearranged-diffuse-large-b-cell-lymphoma-a-dilemma-in-classification
#19
Dina Sameh Soliman, Ahmad Al-Sabbagh, Feryal Ibrahim, Ruba Y Taha, Zafar Nawaz, Sarah Elkourashy, Abdulrazzaq Haider, Susanna Akiki, Mohamed Yassin
According to World Health Organization (WHO) classification (2008), B-cell neoplasms are classified into precursor B-cell or a mature B-cell phenotype and this classification was also kept in the latest WHO revision (2016). We are reporting a male patient in his fifties, with tonsillar swelling diagnosed as diffuse large B-cell lymphoma (DLBCL), germinal center. He received 6 cycles of RCHOP and showed complete metabolic response. Two months later, he presented with severe CNS symptoms. Flow cytometry on bone marrow (BM) showed infiltration by CD10-positive Kappa-restricted B-cells with loss of CD20 and CD19, and downregulation of CD79b...
2017: Case Reports in Hematology
https://www.readbyqxmd.com/read/28712322/is-now-the-time-for-molecular-driven-therapy-for-diffuse-large-b-cell-lymphoma
#20
REVIEW
Alice Di Rocco, Federico De Angelis, Michela Ansuinelli, Robin Foà, Maurizio Martelli
Recent genetic and molecular discoveries regarding alterations in diffuse large B-cell lymphoma (DLBCL) deeply changed the approach to this lymphoproliferative disorder. Novel additional predictors of outcomes and new therapeutic strategies are being introduced to improve outcomes. Areas covered: This review aims to analyse the recent molecular discoveries in DLBCL, the rationale of novel molecular driven treatments and their impact on DLBCL prognosis, especially in ABC-DLBCL and High Grade B Cell Lymphoma...
September 2017: Expert Review of Hematology
keyword
keyword
167493
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"